2838 related articles for article (PubMed ID: 8325955)
1. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
2. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
Anderson RA; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
[TBL] [Abstract][Full Text] [Related]
4. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
5. Suppression of human spermatogenesis by testosterone implants.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
7. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
8. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
9. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
10. Suppression of spermatogenesis by testosterone enanthate in Thai men.
Aribarg A; Sukcharoen N; Chanprasit Y; Ngeamvijawat J; Kriangsinyos R
J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
12. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
[TBL] [Abstract][Full Text] [Related]
13. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
McLachlan RI; O'Donnell L; Stanton PG; Balourdos G; Frydenberg M; de Kretser DM; Robertson DM
J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
[TBL] [Abstract][Full Text] [Related]
16. Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone.
Anderson RA; Wallace EM; Groome NP; Bellis AJ; Wu FC
Hum Reprod; 1997 Apr; 12(4):746-51. PubMed ID: 9159436
[TBL] [Abstract][Full Text] [Related]
17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. V. Localization of higher 5 alpha-reductase activity to the reproductive tract in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Kelly RW; Wu FC
J Androl; 1997; 18(4):366-71. PubMed ID: 9283948
[TBL] [Abstract][Full Text] [Related]
18. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
[TBL] [Abstract][Full Text] [Related]
19. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
[TBL] [Abstract][Full Text] [Related]
20. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
Wu FC; Balasubramanian R; Mulders TM; Coelingh-Bennink HJ
J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
